Тошкент педиатрия тиббиёт институти

SCIENTIFIC COUNCIL DSc.04/30.12.2019.Tib.29.01 ON AWARD 
OF SCIENTIFIC DEGREE OF DOCTOR OF SCIENCES 
AT THE TASHKENT PEDIATRIC MEDICAL INSTITUTE
ANDIJAN STATE MEDICAL INSTITUTE 
ATAJANOVA SHOIRA KHALILOVNA 
PATHOGENETIC ASPECTS OF IRON DEFICIENCY 
ANEMIA IN ADOLESCENT GIRLS 
14.00.09-Pediatrics 
DISSERTATION ABSTRACT OF THE DOCTOR OF
PHILOSOPHY (PhD) ON MEDICAL SCIENCES 
TASHKENT – 2021 

---

---

49 
INTRODUCTION (abstract of the dissertation of the doctor of philosophy 
(PhD)) 
The aim of the study
was to study the pathogenetic aspects of iron deficiency 
in adolescent girls aged 12-14 years in conjunction with indicators of physical 
development, to develop optimal ways of primary prevention and correction of 
IDA for them. 
The object of the study
was 126 adolescent girls with iron deficiency anemia 
aged 12-14 years, who were observed from the 2010-2011 and 2011-2012 
academic years from school No. 24 in the city of Andijan. 
Scientific novelty of the research 
for the first time in adolescent girls aged 12-14 years, the pathogenetic 
features of peripheral blood and iron metabolism in adolescent girls were 
established and traced, depending on the stage of iron deficiency: healthy → LHD 
→ IDA mild → IDA of moderate severity; 
the features of the syndromic characteristics of IDA in adolescent girls were 
determined, depending on the degree and severity of iron deficiency, and the 
weight indicators and prognostic value of each syndrome and symptom in the 
formation of IDA were established; 
for the first time, the pathogenetic features of peripheral blood and iron 
metabolism in adolescent girls were established, depending on their somatic type 
of development, direction of growth, disharmony in terms of physical 
development; 
in girls with IDA at the age of 12-14 years, there is a tendency to the early 
appearance of the first menstruation, proceeding with an accelerated cycle, 
lengthening the duration of one cycle and "lost" blood in it; 
for the first time, the dependence of the development of IDA in adolescent 
girls on the age-related increase in the volume of circulating blood (VCB), leading 
to a decrease in the hematocrit index (HI) and the specific hemoglobin content 
(SHC); 
sufficient efficacy and safety of the drug "Bioferron" have been proved, both 
for prophylactic and therapeutic purposes in the correction of iron deficiency in 
adolescent girls aged 12-14 years.